New drug RC88 shows promise for advanced cancers in early trial
NCT ID NCT05508334
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an injectable drug called RC88 in 41 people with advanced solid tumours who had no other good treatment options. The main goal was to check the drug's safety and find the right dose. The study is now complete, and results will help guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RC88 (an injectable drug)
What this could lead to
If successful, RC88 could offer a new treatment option for people with advanced solid tumours who have not responded to standard therapies.
What could go wrong
This is an early-phase study with only 41 participants, so results may not apply to everyone. The main goal is safety, not yet proving effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Remegen
Beijing, Beijing Municipality, China
-
Remgenen
Beijing, Beijing Municipality, China